Cyberpharmaceuticals
cyberpharmaceuticals
Who We Are
Developing from natural technology
We are a dedicated team of scientists, primarily composed of pharmacists, geneticists, ethnobotanists, and biologists, headquartered in Uruguay. Our passion lies in Nature and its biochemical compounds, inspiring us to discover new treatments for diseases with high morbidity rates. We also embrace cutting-edge technologies, including artificial intelligence and computer simulations, to expedite the discovery and development of innovative pharmaceutical compounds.
Our Mission
Innovative research for animal health
Our current research is focused on animal health, with a particular emphasis on creating natural-origin drugs to combat the canine distemper virus (CDV). Despite the availability of vaccines, recovering infected animals remains a significant challenge due to the high morbidity associated with this highly contagious virus.
CDV poses a serious threat not only to dogs but also to a wide range of other species, including foxes, lynxes, wolves, raccoons, ferrets, seals, and primates. Mortality rates for infected animals range from 50% to 80%, with surviving animals often suffering lasting neurological disorders.
What we do
Precision and innovation to fight animal diseases
We begin with Nature. Our ethnobotanists draw upon traditional knowledge, exploring historical pharmacopeias such as Chinese and Ayurvedic, and collaborating with Indigenous communities to discover plants with medicinal potential.
Our policy ensures that we prioritize plants classified as invasive or non-endangered.
After identifying promising plants, we isolate and analyze their primary compounds to understand their molecular structures.
Leveraging AI algorithms, we then identify compounds with potential antiviral activity against CDV.
Once we identify viable compounds, we collaborate with veterinary laboratories to move towards developing effective treatments.
Our Values and Guidelines
These codes objectively describe the moral values and guidelines that guide the organization
01
Respect for All Life
We value the interconnectedness of species and the equal importance of all life forms.
02
Innovation and Safety
We harness technology to deliver safe, natural cures, striving to protect ecosystems in the process.
03
Local Focus
Our research often begins with plants native to our biomes, especially those considered invasive, promoting ecosystem balance without relying on pesticides.
04
Cultural Respect
We honor traditional plant knowledge and aim to support communities that contribute to our understanding of Nature.
05
Unity and Equality
We celebrate diversity, uphold competence and excellence, and reject any form of discrimination based on race, belief, or orientation.
For Investors
Investing in our token for improvement of animal health
Cyberpharmaceuticals offers a groundbreaking investment model for those seeking a forward-thinking, profitable alternative. Unlike traditional stock markets, where returns can take years to materialize, or crowdfunding models, where supporters donate without direct gains, Cyberpharmaceuticals introduces its own cryptocurrency, CYPH, based on and audited by the Ethereum blockchain.
With a limited supply of 100 million tokens, CYPH offers investors the chance to acquire it directly from Cyberpharmaceuticals. Early investors can purchase CYPH at a discounted rate, securing a favorable position in the project’s initial phases. Additionally, Cyberpharmaceuticals plans periodic token buybacks, reducing the total supply and increasing CYPH’s value as projects progress and generate profits.
Another key advantage is the opportunity for active involvement in the company’s future. CYPH holders will be able to vote on strategic matters, such as research and development focuses and governance policies, ensuring that investor interests align with the growth and success of Cyberpharmaceuticals.
For further information on the CYPH token model contact us in tokens@cyberpharmaceuticals.org and please access the whitepaper here:
Research and Development Progress
The Canine Distemper Virus (CDV) was first sequenced in 1997, and numerous strains have since been identified and analyzed. These advancements have significantly improved the understanding of viral structures, aiding the development of innovative therapies. The latest sequencing effort, recorded in 2021, is available in this article: PMC Article.
Cyberpharmaceuticals has initiated the screening phase of Uruguayan plants, prioritizing invasive species or those not listed as endangered, in search of bioactive molecules with potential activity against viruses in the Paramyxoviridae family.
Simultaneously, the virus’s genetic code is being analyzed, and potential target sequences are being identified for future laboratory testing.
Financial Progress
The Cyberpharmaceuticals token contract, audited on the Ethereum blockchain, has been successfully approved.
The next step will be the token issuance and its asset backing structure, enabling investors to access the asset. This stage is expected to be completed by April 2025.
General Progress
Starting next year, Cyberpharmaceuticals will participate in events across Uruguay, aiming to attract partners and investors interested in supporting the project. The dates and locations of these events will be announced on this page soon.
Scientific Progress
Virus Genetic Sequencing
100%
Natural Molecules Choice
24%
AI Topographical Simulations
0%
Administrative Progress
Ethereum Token Concract Validation
100%
Ethereum Token Liberation
90%
Project Divulgation
0%
Meetings and Events 2025
12%
follow the latest news
Contact Us
For inquiries, please reach us at:
Email: contact@cyberpharmaceuticals.org
Or use the form on the side
Work with us: hr@cyberpharmaceuticals.org
For inquiries, please reach us at:
Email: contact@cyberpharmaceuticals.org
Or use the form below
Work with us: hr@cyberpharmaceuticals.org
Cyberpharmaceuticals R&D
Cyberpharmaceuticals
©2024 Cyberpharmaceuticals Copyright ~ All Right Reserved.